Literature DB >> 33548061

Implication of CD69+ CD103+ tissue-resident-like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma.

Hyung-Don Kim1,2, Seongju Jeong2, Seongyeol Park2, Yong Joon Lee2, Young Seok Ju2, Danbee Kim1, Gi-Won Song3, Jae Hoon Lee3, Sang-Yeob Kim4, Jaehoon Shin4, Eui-Cheol Shin2, Shin Hwang3, Changhoon Yoo1, Su-Hyung Park2.   

Abstract

BACKGROUND: The heterogeneous immune landscapes of intrahepatic cholangiocarcinoma (ICC) remain largely unknown. Here we aimed to investigate the implications of tissue-resident memory (TRM)-related features of tumour-infiltrating CD8+ T cells (CD8+ TILs) from ICC patients.
METHODS: From ICC patients, we obtained blood samples and ICC surgical specimens (n = 33). We performed multicolour flow cytometry, multiplexed immunohistochemistry and RNA sequencing.
RESULTS: When compared to peripheral CD8+ T cells, the CD8+ TILs included significantly higher proportions of the CD69+ CD103- and CD69+ CD103+ TRM-like subsets (P < .001 for both). Relative to CD69- and CD69+ CD103- cells, the CD69+ CD103+ CD8+ TILs harboured higher levels of T-cell markers representing tumour specificity (ie CD39), proliferation (ie Ki-67) and T-cell activation (ie HLA-DR and CD38) (all P < .001). Moreover, compared to the stroma, the tumour margin and core density each had a significantly higher density of CD103+ CD8+ TILs (P < .001 for both). ICCs with high proportions of CD69+ CD103+ cells displayed higher levels of parameters associated with response to immune checkpoint inhibitors (ICIs)-including number of CD8+ TIL infiltrates (P = .019), PD-L1 expression in the tumour (P = .046) and expression of the T cell-inflamed gene signature (P < .001). ICCs with lower proportions of CD69+ CD103+ CD8+ TILs exhibited significant enrichment of genes related to the Wnt/β-catenin (P < .001) and TGF-β pathways (P = .002).
CONCLUSION: CD69+ CD103+ TRM-like CD8+ TILs represent prominent tumour-specific immune responses and hold promise as a potential therapeutic target in ICC patients. Differential TRM-related features of ICCs may help develop future immunotherapeutic strategies such as maximizing TRM responses or inhibiting pathways contributing to immune evasion.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cholangiocarcinoma; immune checkpoint inhibitor; tissue-resident memory T cells; tumour-infiltrating lymphocytes

Year:  2021        PMID: 33548061     DOI: 10.1111/liv.14814

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

Review 1.  Association of CD103+ T cell infiltration with overall survival in solid tumors of the digestive tract and its potential in anti-PD-1 treatment: A review and meta-analysis.

Authors:  Wei Wei; Yun Ding; Jiajia He; Jun Wu
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2022-03-28       Impact factor: 1.245

2.  Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases.

Authors:  Cristina Faccani; Gianluca Rotta; Francesca Clemente; Maya Fedeli; Danilo Abbati; Francesco Manfredi; Alessia Potenza; Achille Anselmo; Federica Pedica; Guido Fiorentini; Chiara Villa; Maria P Protti; Claudio Doglioni; Luca Aldrighetti; Chiara Bonini; Giulia Casorati; Paolo Dellabona; Claudia de Lalla
Journal:  Life Sci Alliance       Date:  2022-06-03

Review 3.  The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.

Authors:  Dong Liu; Lara Rosaline Heij; Zoltan Czigany; Edgar Dahl; Sven Arke Lang; Tom Florian Ulmer; Tom Luedde; Ulf Peter Neumann; Jan Bednarsch
Journal:  J Exp Clin Cancer Res       Date:  2022-04-07

Review 4.  The evolving role of tissue-resident memory T cells in infections and cancer.

Authors:  Sasitorn Yenyuwadee; Jose Luis Sanchez-Trincado Lopez; Rushil Shah; Pamela C Rosato; Vassiliki A Boussiotis
Journal:  Sci Adv       Date:  2022-08-17       Impact factor: 14.957

Review 5.  Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.

Authors:  Hengsong Cao; Tian Huang; Mingrui Dai; Xiangyi Kong; Hanyuan Liu; Zhiying Zheng; Guoqiang Sun; Guangshun Sun; Dawei Rong; Zehua Jin; Weiwei Tang; Yongxiang Xia
Journal:  Int J Biol Sci       Date:  2022-08-21       Impact factor: 10.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.